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Heart failure (HF) is one of the most pervasive complications occurring in patients with type 2 diabetes (T2D). The risk of HF with preserved (HFPEF) and reduced (HFREF) ejection fraction is four-to five-fold higher among patients with T2D as compared with those without the condition, and is associated with a poor prognosis, with a median survival of 4 years from the time of diagnosis. 1, 2 Although fasting plasma glucose levels and glycated haemoglobin (HbA 1c ) are significantly associated with an increased risk of HF, 3 intensive glycaemic control with oral glucose-lowering agents or insulin has failed to reduce the risk of HF-related events as compared with standard treatment. 4, 5 In the recent EMPA-REG OUTCOME V R trial, the sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin was the first glucose-lowering drug able to reduce cardiovascular mortality and hospitalizations for HF (HHF) in T2D patients at high cardiovascular (CV) risk. 6 In this trial, 7020 patients were randomized to receive 10 or 25 mg of empagliflozin or placebo once daily. After a median observation time of 3.1 years, empagliflozin (pooled 10 and 25 mg doses) significantly reduced the primary composite outcome of CV death, non-fatal myocardial infarction (MI), or non-fatal stroke [hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.74-0.99; P = 0.04 for superiority]. Although empagliflozin did not reduce the rates of MI or stroke, it significantly reduced death from CV causes, HHF, and death from any cause by 38, 35, and 32%, respectively. 6 A second analysis of the EMPA-REG OUTCOME V R -aimed at elucidating the impact of empagliflozin on HF-related outcomes-showed that empaglifozin reduces the rate of HHF and CV death, with a consistent benefit in patients with and without baseline HF. 7 Whether empagliflozin is equally effective among different categories of HF risk remain to be elucidated. In the current issue of the journal, Fitchett and associates present a further analysis of the EMPA-REG OUTCOME V R , exploring the effects of empagliflozin across the spectrum of HF in patients with T2D. 8 In patients without HF at baseline (89.9%), the 5-year risk for incident HF using the nine-variable Health ABC HF Risk score was employed to classify the study population into different HF risk categories: low to average (<10%), high (10-20%), and very high (>20%). Based on this score, 67.2% of the population was classified as having low to average, 24.2% high, and 5.1% very high 5-year risk of developing HF. The investigators found that empagliflozin exerted a similar reduction of CV death and HFF across the different risk categories ( Figure 1 ). In line with their previous analysis, 7 in the present study CV mortality was also significantly reduced among patients either with HF at baseline or who had an incident HF episode during follow-up (HR 0.67, 95% CI 0.47-0.97). Separation of the cumulative incidence curves appeared early, and the reduction of risk persisted for the duration of the trial in patients at low to average, high, and very high risk of HF. 8 Taken together, these findings show for the first time that an SGLT-2 inhibitor, namely empagliflozin, reduces CV mortality and HHF in patients at both high and lower risk, as well as in patients with or without either baseline or incident HF. An increasing body of evidence confers validity to the results of Fitchett et al. The recent CANVAS trial showed that treatment with the SGLT-2 inhibitor canagliflozin (100 mg daily with an optional increase to 300 mg starting from week 13) significantly reduced the composite primary endpoint of death from CV causes, non-fatal MI, or non-fatal stroke by 14% (HR 0.86, 95% CI 0.75-0.97; P < 0.001 for non-inferiority, P = 0.02 for superiority) and HHF by 33% (HR 0.67, 95% CI 0.52-0.87) in 10 142 participants with T2D and high CV risk. 9 Along the same line, a study on 309 056 patients comparing HHF and death in patients newly initiated on any SGLT-2 inhibitor vs. other glucose-lowering drugs in six countries showed that SGLT-2 inhibitor use was associated with lower rates of HHF (HR 0.61, 95% CI 0.51-0.73; P < 0.001); death (HR 0.49, 95% CI 0.41-0.57; P < 0.001); and HHF or death (HR 0.54, 95% CI 0.48-0.60; P < 0.001), with no significant heterogeneity by country. 10 Finally, a recent meta-analysis including 81 trials with a total of 37 195 patients and mean follow-up of 89 weeks showed that SGLT-2 inhibitors were associated with a Several mechanisms may contribute to explain the early beneficial effects of empagliflozin on CV mortality and HHF. SGLT-2 inhibition has been associated with weight loss, improved glucose and blood pressure control, osmotic diuresis, reduced arterial stiffness, as well as reduction in sympathetic nerve activation. 12 SGLT-2 inhibitors also increase the concentration of circulating ketone bodies, which might provide an alternative energy source for the diabetic heart in the presence of insulin resistance. 12 However, the very early effects of empagliflozin on CV outcomes-occurring already after 12 weeks-cannot be entirely explained by its effects on glycaemic control, blood pressure, or osmotic diuresis. Previous glucose-lowering trials achieving more stringent HbA1c goals failed to reduce CV mortality and HHF. 4 Similarly, earlier studies with blood pressure-lowering drugs took much longer to show unequivocal reductions in CV outcomes. 13 Packer et al. have recently hypothesized that the benefits of SGLT-2 inhibitors in HF may be mediated by the inhibition of sodium-hydrogen exchange rather than the effect on glucose reabsorption. 14 The sodium-hydrogen exchanger, which is responsible for the majority of sodium tubular reuptake following filtration, is highly active in HF patients, and may be responsible for resistance both to diuretics and to endogenous natriuretic peptides, important prognostic factors in patients with HF. 14 In addition, cardiac inhibition of sodium-hydrogen exchange by empagliflozin may in turn lead to a reduction in hypertrophy, fibrosis, remodelling, and systolic dysfunction. 14 Mortality in T2D patients with HF is mostly driven by the presence of co-morbidities, namely renal insufficiency. 12 In this regard, empagliflozin is associated with a slower progression of kidney disease and lower rates of clinically relevant renal events than was placebo when added to standard care (HR 0.61, 95% CI 0.53-0.70; P < 0.001). 15 Based on its positive effects on the cardio-renal axis, the recent ESC guidelines on the management of HF have introduced the possibility to use empagliflozin in patients with T2D 'to prevent or delay the onset of HF, and to prolong life'. 16 The findings by Fitchett et al. 8 are timely and of high clinical impact.
However, further studies specifically designed to investigate the efficacy and safety of empagliflozin and other SGLT-2 inhibitors on HFrelated outcomes are warranted. In the EMPAREG OUTCOME V R , HF admissions were a pre-specified secondary safety endpoint, and were not centrally adjudicated. Moreover, no cardiac-specific measures (i.e. ejection fraction, NT-proBNP) were available in this study, and investigator-reported HF was based on the narrow standardized MedDRA query (SMQ) 'cardiac failure', an approach which may have underestimated HF prevalence and incidence over the duration of the study. Moreover, the number of events (CV death and HHF) in the different HF risk classes was rather low to explore fully the benefits of empagliflozin in this setting. Finally, CV deaths registered within the three HF risk groups might be the result of different factors (i.e. MI, arrhythmias) and not necessarily the consequence of HF.
Overall, the present study provides novel insights to believe that empagliflozin, and perhaps other SGTL-2 inhibitors, may act across the spectrum of diabetic heart disease, from early stages of diabetic cardiomyopathy to congestive HF. Relevant haemodynamic and renal effects as well as low risk of hypoglycaemia make SGLT-2 inhibitors a unique class of antidiabetic drugs to be employed in combination with well-established glucose-lowering medications (i.e. metformin), with the goal of preventing or reducing HF burden in T2D patients. Notably, the effect of SGLT-2 inhibitors on glucose elimination is proportional to glycaemic levels, being modest or even negligible in conditions of mild hyperglycaemia. 13 This 'self-limiting' action of SGLT-2 inhibitors may suggest their use also in patients without diabetes (i.e. pre-diabetes, obesity, hypertension) to prevent adverse cardiac remodelling and dysfunction. Future studies will help us to characterize further and appreciate the potential of empagliflozin and other SGLT-2 inhibitors to fight the epidemic of HF.
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